The use of fibric acid derivatives in cardiovascular prevention

Current Treatment Options in Cardiovascular Medicine

Volumn 13, Issue 4, 2011, Pages 335-342

  Khoury, Nadia ^a   Goldberg, Anne Carol ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALBUMINURIA; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLELITHIASIS; CORONARY ARTERY DISEASE; DIET THERAPY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID COMPOSITION; LOW DRUG DOSE; MYALGIA; RASH; RETINOPATHY; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; STROKE; TREATMENT OUTCOME;

EID: 80051665684     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-011-0128-7     Document Type: Article

References (31)

1. World Health Organization Cardiovascular Diseases Fact Sheet. Available at http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed February 2011.
2. C Baigent A Keech PM Kearney, et al. 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267 1278 16214597 10.1016/S0140-6736(05)67394-1 1:CAS:528:DC%2BD2MXhtVOlu7fM (Pubitemid 41416582)
3. G Assmann H Schulte 1992 Role of triglycerides in coronary artery disease: Lessons from the prospective cardiovascular Münster study Am J Cardiol 70 H10 H13 10.1016/0002-9149(92)91084-H
4. RC Turner H Millns HA Neil, et al. 1998 Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 316 823 828 9549452 1:STN:280: DyaK1c3htVKhsg%3D%3D (Pubitemid 28112428)
5. Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
6. SM Grundy JI Cleeman CN Merz, et al. 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 227 239 15249516 10.1161/01.CIR.0000133317.49796.0E (Pubitemid 38924592)
7. WV Brown 2007 Expert commentary: The safety of fibrates in lipid-lowering therapy Am J Cardiol 99 suppl 19C 21C 17368273 10.1016/j.amjcard.2006.11.017 1:CAS:528:DC%2BD2sXjtFGlt7Y%3D (Pubitemid 46412227)
8. AS Wierzbicki 2009 Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia Curr Opin Cardiol 24 372 379 19424060 10.1097/HCO.0b013e32832c0b3d
9. The Coronary Drug Project Research Group 1975 Clofibrate and niacin in coronary heart disease J Am Med Assoc 231 360 381 10.1001/jama.231.4.360
10. WHO Cooperative trial committee of principal investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J. 1978;40:1069-118.
11. MH Frick O Elo K Haapa, et al. 1987 Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1237 1245 3313041 10.1056/NEJM198711123172001 1:STN:280:DyaL1c%2FjvFSjtw%3D%3D (Pubitemid 17147964)
12. P Koskinen M Manttari V Manninen, et al. 1992 Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study Diabetes Care 15 820 825 1516498 10.2337/diacare.15.7.820 1:STN:280:DyaK38zoslSltA%3D%3D
13. HB Rubins SJ Robins D Collins, et al. 1999 Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 410 418 10438259 10.1056/NEJM199908053410604 1:CAS:528:DyaK1MXltlyltbw%3D (Pubitemid 29362514)
14. RS Elkeles JR Diamond C Poulter, et al. 1998 Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study Diabetes Care 21 641 648 9571357 10.2337/diacare.21.4.641 1:STN:280:DyaK1c3jt1ynug%3D%3D (Pubitemid 28172949)
15. T Meade R Zuhrie C Cook, et al. 2002 Bezafibrate in men with lower extremity arterial disease: Randomised controlled trial BMJ 325 1139 12433762 10.1136/bmj.325.7373.1139 1:CAS:528:DC%2BD38Xps1KitL4%3D
16. The BIP Study Group 2000 Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study Circulation 102 21 27
17. I Goldenberg M Benderly R Sidi, et al. 2009 Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial) Am J Cardiol 103 4 45 10.1016/j.amjcard.2008.08.033
18. Diabetes Atherosclerosis Intervention Study Investigators 2001 Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study Lancet 357 905 910 10.1016/S0140-6736(00)04209-4 (Pubitemid 32247277)
19. A Keech RJ Simes P Barter, et al. 2005 Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial Lancet 366 1849 1861 16310551 10.1016/S0140-6736(05)67667-2 1:STN:280:DC%2BD2MnjtVCnsg%3D%3D (Pubitemid 41690113)
20. R Scott R O'Brien G Fulcher, et al. 2009 Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 493 498 18984774 10.2337/dc08-1543 1:CAS:528:DC%2BD1MXjvVyqt7s%3D
21. SM Grundy GL Vega Z Yuan, et al. 2005 Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial) Am J Cardiol 95 462 468 15695129 10.1016/j.amjcard.2004.10.012 1:CAS:528: DC%2BD2MXptlClsA%3D%3D (Pubitemid 40247539)
22. HN Ginsberg MB Elam LC Lovato, et al. 2010 Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 1563 1574 20228404 10.1056/NEJMoa1001282 ACCORD-Lipid is a large study comparing the combination of simvastatin and fenofibrate to simvastatin alone on cardiovascular outcomes in patients with diabetes. Benefit was only seen in patients with high triglyceride and low HDL cholesterol levels.
23. AS Wierzbicki J Morrell D Hemsley, et al. 2010 The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis Curr Med Res Opin 26 2141 2146 20662558 10.1185/03007995.2010. 503429 1:CAS:528:DC%2BC3cXhtVWqu7fP
24. FM Sacks VJ Carey JC Fruchart 2010 Combination lipid therapy in type 2 diabetes N Engl J Med 363 692 693 20842772 10.1056/NEJMc1006407 1:CAS:528:DC%2BC3cXhtVaktbvL
25. M Jun C Foote J Lv, et al. 2010 Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 1875 1884 20462635 10.1016/S0140-6736(10)60656-3 1:CAS:528:DC%2BC3cXmsleksrc%3D This is a useful, detailed meta-analysis of most fibrate outcomes trials.
26. M Elam LC Lovato H Ginsberg 2011 Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective Curr Opin Lipidol 22 55 61 21102326 10.1097/MOL.0b013e328341a5a8 1:CAS:528:DC%2BC3MXlsFWqsg%3D%3D This is an analysis of the outcomes of ACCORD-Lipid, placing it in perspective with other fibrate studies.
27. M Rubenfire RD Brook RS Rosenson 2010 Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events Am J Med 123 892 898 20920687 10.1016/j.amjmed.2010.03.024 1:CAS:528:DC%2BC3cXht1eqtLfK
28. MJ Chapman 2003 Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives Atherosclerosis 171 1 13 14642400 10.1016/S0021-9150(03)00156-4 1:CAS:528:DC%2BD3sXpt1eqsb8%3D (Pubitemid 37474095)
29. MH Davidson A Armani JM McKenney, et al. 2007 Safety considerations with fibrate therapy Am J Cardiol 99 suppl 3C 18C 17368275 10.1016/j.amjcard.2006.11. 016 1:CAS:528:DC%2BD2sXjtFGltL4%3D (Pubitemid 46412226)
30. S Abourbih KB Filion L Joseph, et al. 2009 Effect of fibrates on lipid profiles and cardiovascular outcomes: A systematic review Am J Med 122 962.e1 962.e8 10.1016/j.amjmed.2009.03.030
31. PH Jones MH Davidson 2005 Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin Am J Cardiol 95 120 127 15619408 10.1016/j.amjcard.2004.08.076 1:CAS:528:DC%2BD2cXhtFahs7jE (Pubitemid 40051126)